Skip to main content
Article
Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium
Psychiatry Publications and Presentations
  • Kristina M. Deligiannidis, University of Massachusetts Medical School
UMMS Affiliation
Department of Psychiatry
Date
5-1-2010
Document Type
Article
Medical Subject Headings
Anticonvulsants; Antimanic Agents; Depressive Disorder; Drug Monitoring; Epilepsy; Female; Humans; Lithium Compounds; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Serotonin Uptake Inhibitors; Triazines
Disciplines
Abstract

Recently, guidelines for antenatal management of depression were published.1 Psychotherapy alone may be an appropriate treatment for some women, while psychopharmacotherapy may be indicated in others. Use of psychopharmacotherapy during pregnancy and the postpartum involves complex clinical decisions based on the risks and benefits and alternatives to medications. The aim of effective treatment is to minimize maternal and fetal exposure to psychiatric illness by optimally treating it with the minimum effective dose regimen. One variable that complicates psychopharmacotherapy is that dosing often requires adjustment to maintain therapeutic effects, particularly in late pregnancy. The current article focuses on those factors that affect dosing in pregnancy.

Rights and Permissions
Citation: Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: Recommendations for SSRIs, lamotrigine and lithium. Journal of Clinical Psychiatry 71(5):649-650, 2010.
Related Resources
Link to article in PubMed
PubMed ID
20492855
Citation Information
Kristina M. Deligiannidis. "Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium" Vol. 71 Iss. 5 (2010) ISSN: 1555-2101
Available at: http://works.bepress.com/kristina_deligiannidis/2/